Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention

Not Applicable

• Conditions: Restenosis; Peripheral Arterial Disease
• Interventions: Drug: Placebo; Drug: Paclitaxel

• Registration Number: NCT01599078
• Lead Sponsor: Midwest Cardiovascular Research Foundation

Brief Summary

The purpose of this study is to assess the safety and efficacy of administering intra-arterial paclitaxel in the femoropopliteal arteries via the TAPAS catheter following percutaneous revascularization to prevent restenosis.

Detailed Description

Peripheral artery disease (PAD) of the lower extremities is an extremely prevalent disorder and is an important cause of morbidity that affects more than 10 million people in the United States. This disorder is typically caused by atherosclerosis that limits blood flow to the limbs, particularly due to stenosis or occlusion of the superficial femoral artery (SFA) and/or popliteal artery. Although many patients are asymptomatic or are treated with lifestyle changes, such as exercise therapy, or pharmacological treatment, including statins and anti-platelet therapy, about 10-15% of patients have progressive symptoms which in severe cases may lead to amputation.

Endovascular treatment with percutaneous vascular intervention (PVI), which includes percutaneous transluminal angioplasty (PTA), stenting, atherectomy and thrombolytic therapy, can provide excellent acute success rates greater than 90-95% However, the intermediate to long-term patency rates of these arteries is hampered by neointimal hyperplasia resulting in restenosis of the artery. This occurs with all endovascular therapy to some degree in both the coronary and peripheral arena. With PVI in the superficial femoral and popliteal arteries the restenosis rates are approximately 30-40% at 12 months, depending on the complexity and severity of the disease.

In the coronary field, stents are now coated with anti-restenotic pharmacologic agents (drug eluting stents-DES) such as paclitaxel and sirolimus-like drugs that prevent neointimal growth. There have been published reports of significant efficacy in preventing restenosis in the SFA by coating balloons with paclitaxel (drug eluting balloons-DEB) as well as a nitinol stent. Despite the fact that these products are CE Mark approved and available in Europe, currently there are no US FDA approved drug-eluting devices for use in PVI. Thus, there remains a need for an alternative therapy to prevent restenosis in the SFA following endovascular intervention.

Administration of intra-arterial paclitaxel mixed with iodinated contrast has been shown to inhibit restenosis in a porcine coronary model.

Delivering paclitaxel intra-arterially in the coronary tree following stent implantation has shown benefit in reducing the incidence of restenosis. The novel Targeted Adjustable Pharmaceutical Application System (TAPAS)-TAPAS Catheter Therapeutic Infusion System (ThermopeutiX, San Diego, CA, USA)-is a drug delivery catheter that consists of a proximal and distal occlusion balloon with an adjustable length that allows a drug to dwell in a specific segment of the artery for a period of time. The drug can then be aspirated and discarded to avoid systemic exposure.

The PacTAP study is a randomized, double blind, placebo-control study to assess the safety and efficacy of delivering intra-arterial paclitaxel via the TAPAS catheter following PVI to prevent restenosis.

Study Timeline

• Study Start: 2012-01
• Status Verified: 2012-05
• Study First Submitted: 2012-05-13
• Study First Submitted QC: 2012-05-13
• Last Update Submitted: 2012-05-13
• Study First Posted: 2012-05-15
• Last Update Posted: 2012-05-15
• Primary Completion: 2013-01
• Study Completion: 2014-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Age ≥ 18 years old.
• Subject able to provide informed consent and agree to all follow up requirements.
• Peripheral arterial disease with Rutherford Class 2-5.
• Successful percutaneous revascularization of the femoropopliteal artery (< 20% residual stenosis by visual estimate) using standard techniques per discretion of the local operator.
• The femoropopliteal Reference Vessel Diameter (RVD) must be ≥4.0 mm and ≤7.0 mm

Exclusion Criteria

• Patient is pregnant or breast feeding. (Female subjects of childbearing potential must have negative serum pregnancy test the day of the procedure.)
• Life expectancy < 12 months.
• Contraindication to aspirin, anti-platelet/anti-coagulant therapies required for procedure/follow up.
• Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure.
• Known allergy to paclitaxel.
• Uncontrolled hypercoagulability or history of HIT or HITTS syndrome.
• Simultaneous enrollment in another investigational device or drug study.
• Previous intervention of the target limb with a drug eluting stent or drug eluting balloon.
• Absence of at least 1 TIMI-3 vessel run off into the foot.
• Total bilirubin > 2x upper limit of normal (ULN).
• ALT or AST > 3x ULN.
• Platelet count < 100,000/mm3.
• White blood cell count < 1.5/mm3.
• Any evidence of perforation or dye extravasation during the index procedure, even if successfully treated with a covered stent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Paclitaxel	Paclitaxel	-

Primary Outcome Measures

Name	Time	Method
Primary Patency	6 months	Loss of primary patency will occur for any clinically driven Target Lesion Revascularization (TLR) or a Peak Systolic Velocity Ratio (PSVR) of \> 2.5 on Duplex Ultrasound (DUS)
Primary Safety	30 days	Freedom from death, major amputation in the target limb, or Target Lesion Revascularization (either surgical or endovascular)

Secondary Outcome Measures

Name	Time	Method
Primary Patency at 12 months	12 months	Loss of primary patency will occur for any clinically driven Target Lesion Revascularization (TLR) or a Peak Systolic Velocity Ratio (PSVR) of \> 2.5 on Duplex Ultrasound (DUS)
Primary Assisted Patency	6 and 12 months	Patency of the target vessel regardless of secondary interventions performed to restore blood flow after restenosis.
Secondary Patency	6 and 12 months	Patency of the target vessel regardless of secondary interventions performed to restore blood flow after reocclusion.
Functional Status	30 days, 6 months, and 12 months	Walking Impairment Questionnaire (WIQ), and Rutherford Classification.
Secondary Safety	30 days, 6 months, and 12 months	Any adverse events associated with the use of paclitaxel, such as, but not limited to: hypotension, anaphylactic reactions, nausea, vomiting, diarrhea, pancytopenia, neuropathy, alopecia.

Trial Locations

Locations (1)

Trinity Medical Center; 🇺🇸 Bettendorf, Iowa, United States